Merck Shares Fall 9% Despite Earnings Beat and Strong Demand for Key Drugs
Merck reported second-quarter revenue and adjusted earnings that exceeded Wall Street’s expectations, driven by strong sales from its blockbuster cancer drug Keytruda and other treatments in...